Clementine and Haleon collaborate in a trial to add ‘mind-care’ to everyday health products
Clementine - the UK startup that uses hypnotherapy to support emotional wellbeing – announced a new trial collaboration with global consumer health company, Haleon, working with its leading oral health brand, Sensodyne.
Together, the two companies seek to redefine traditional oral care routines by leveraging the power of everyday habits and bridging the gap between physical products and digital therapeutics. This collaboration marks an exciting milestone in the oral health industry and aims to change the way people engage with their health beyond the products they use.
Starting this June, the United Kingdom will become the testing ground for this trial. up to 20,000 packs of Sensodyne will be labelled with a unique QR code which, when scanned using a consumer’s smartphone, unlocks an exclusive Clementine mindset ritual, specially designed to complement their daily teeth-brushing regimen.
Tapping into the average routine of someone brushing their teeth twice per day, there will be seven morning and seven evening sessions available. These transformative experiences - each lasting two minutes to align with the recommended brushing time - will use proven techniques to shape individuals' mindsets for the day ahead and help them unwind in preparation for a restful night’s sleep.
This experiment demonstrates the innovative outcomes which can be achieved by Haleon in partnership with the startup community via its disruptive innovation arm, NEXT. Its Re/Wire programme is aimed at discovering and scaling early-stage consumer health innovators. This collaboration exemplifies a shared commitment to drive experimentation and innovation in the healthcare industry, providing invaluable insights for future endeavors.
"We believe self-care routines and rituals will be at the heart of better consumer health experiences in the future, " says Sarah Jones, Brand Experience Director for Haleon NEXT. "Through this experiment, we're interested to learn how consumers really engage with new types of therapeutic content, helping us deliver better all-round health outcomes beyond our world-leading brands and products.“
Kim Palmer, the founder of Clementine, adds: “We are beyond excited to collaborate with Haleon and Sensodyne to create a whole new way for people to engage with their much-loved health products. We joined the Re/Wire programme in 2022 with the sole purpose to figure out a way to partner together with our shared mission of creating better everyday health outcomes. We believe there is a huge opportunity to add ‘mind-care’ as a new ingredient to everyday products that so many people use. If we could help to take self-care off people’s already lengthy to-do lists by adding self-care into product consumption, it’s got to be good for people and society as a whole.”
About Clementine:
Clementine, is a health start-up dedicated to transforming people’s mindsets through the power of digital therapy. Clementine participated in the second cohort of the Re/Wire Health Studio, operated by Haleon NEXT.
About Haleon NEXT:
Haleon NEXT is the disruptive growth engine for Haleon, focused on the creation and scaling of net-new products, services and platform businesses across everyday health.
About Haleon:
Haleon (LSE / NYSE: HLN) is a global leader in consumer health, with the purpose to deliver better everyday health with humanity. Haleon’s product portfolio spans five major categories - Oral Health, Pain Relief, Respiratory Health, Digestive Health and Other, and Vitamins, Minerals and Supplements (VMS). Its long-standing brands - such as Advil, Sensodyne, Panadol, Voltaren, Theraflu, Otrivin, Polident, parodontax and Centrum - are built on trusted science, innovation and deep human understanding.